獲得性孤兒血病治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、按疾病適應症、按配銷通路、按地區和競爭細分，2020-2030F

2024 年全球獲得性孤兒血液疾病治療市場價值為 79.5 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 7.80%。後天性孤兒血液疾病是一個術語，涵蓋一組罕見且常常危及生命的醫療狀況，這些狀況會影響血液及其成分（例如紅血球、白血球、血小板），並且不是遺傳的，而是在人的一生中獲得的。這些血液疾病不是天生的，也不是基因遺傳的。相反，它們是在人的一生中發展或獲得的，通常是由於各種誘因或潛在的健康狀況。獲得性孤兒血液疾病的診斷、治療和管理通常需要血液學家或其他擅長治療罕見血液疾病的醫療保健提供者的專門護理。治療方法可能包括輸血、免疫抑制療法、標靶療法，以及在某些情況下包括骨髓移植。

基因組學、免疫學和分子生物學等醫學研究的不斷進步加深了我們對這些疾病發病機制的理解。這些知識支持有針對性的治療和治療創新的發展。孤兒藥資格提供的監管獎勵措施（如延長市場獨佔期、稅收抵免和降低開發成本）鼓勵製藥公司投資於罕見疾病的研發。患者權益團體和組織在推動研究、提高意識和倡導改善治療機會方面發揮關鍵作用。他們的努力有助於加速後天孤兒血液疾病領域的進步。基因療法、單株抗體和免疫調節劑等新型治療方式的出現擴大了後天性孤兒血液疾病的治療選擇範圍。診斷技術和製程的進步使得獲得性孤兒血液疾病的診斷更加準確、及時。這使得早期干預和治療成為可能。

主要市場促進因素

醫學研究的進步

主要市場挑戰

獲得治療

主要市場趨勢

擴大准入計劃

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球獲得性孤兒血液疾病治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依療法分類（重組因子、免疫球蛋白輸注療法、活化凝血酶原複合物濃縮物、血小板生成素受體激動劑、其他）
  • 依疾病指徵分類（後天性粒細胞缺乏症、後天性血友病、後天性血管性血友病症候群、陣發性睡眠性血紅素尿症 (PNH)、骨髓增生異常症候群、其他）
  • 按配銷通路（醫院藥房、零售藥房、其他）
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區後天性孤兒血液疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲後天性孤兒血病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美獲得性孤兒血液疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲後天孤兒血病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲獲得性孤兒血液疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球獲得性孤兒血液疾病治療市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Alexion Pharmaceuticals, Inc.
• Amgen, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Sanofi SA
• GlaxoSmithKline plc
• Cyclacel Pharmaceuticals Inc.
• Onconova Therapeutics, Inc
• Incyte Corporation
• CTI BioPharma Corp

第 17 章：策略建議

第18章調查會社について,免責事項

Global Acquired Orphan Blood Diseases Therapeutics Market was valued at USD 7.95 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.80% through 2030. Acquired orphan blood diseases is a term that encompasses a group of rare and often life-threatening medical conditions that affect the blood and its components (e.g., red blood cells, white blood cells, platelets) and are not inherited but acquired during a person's lifetime. These blood diseases are not present at birth or inherited through genetics. Instead, they develop or are acquired during a person's life, often due to various triggers or underlying health conditions. Diagnosis, treatment, and management of acquired orphan blood diseases often require specialized care from hematologists or other healthcare providers with expertise in rare blood disorders. Treatment approaches may include blood transfusions, immunosuppressive therapies, targeted therapies, and, in some cases, bone marrow transplantation.

Ongoing advancements in medical research, including genomics, immunology, and molecular biology, have deepened our understanding of the pathogenesis of these diseases. This knowledge supports the development of targeted therapies and treatment innovations. Regulatory incentives provided by orphan drug designations, such as extended market exclusivity, tax credits, and reduced development costs, encourage pharmaceutical companies to invest in research and development for rare diseases. Patient advocacy groups and organizations play a pivotal role in driving research, raising awareness, and advocating for improved access to treatments. Their efforts help accelerate progress in the field of acquired orphan blood diseases. The emergence of novel treatment modalities, including gene therapies, monoclonal antibodies, and immunomodulatory agents, has expanded the range of therapeutic options available for acquired orphan blood diseases. Advances in diagnostic techniques and technologies have led to more accurate and timely diagnoses of acquired orphan blood diseases. This enables early intervention and treatment.

Key Market Drivers

Advancements in Medical Research

Medical research has deepened our understanding of the underlying mechanisms and pathophysiology of acquired orphan blood diseases. This knowledge helps identify novel therapeutic targets and pathways for intervention. For instance, in February 2025, a new 3D lung model will revolutionize respiratory medicine research. This advanced model replicates lung structure and function, enabling more accurate drug testing and disease modeling. It offers a powerful tool for studying conditions like asthma and COPD, accelerating the development of innovative treatments and improving patient outcomes. Research efforts have led to the development of targeted therapies that address the specific molecular and cellular abnormalities associated with these diseases. Targeted treatments often offer better efficacy and safety profiles compared to traditional therapies. Research has contributed to the identification of biomarkers and genetic markers associated with these diseases. Biomarkers enable early diagnosis, disease monitoring, and personalized treatment approaches. Ongoing research supports drug discovery and development programs aimed at creating innovative and more effective therapeutics. This includes the development of monoclonal antibodies, gene therapies, and small molecule drugs. Advances in clinical trial design and methodology, including adaptive trials and innovative endpoints, facilitate the evaluation of potential therapies. Clinical trials are essential for assessing treatment safety and efficacy. Medical research has led to the creation of patient registries and databases for rare diseases. These registries facilitate data collection, epidemiological studies, and clinical trial recruitment.

Key Market Challenges

Access to Treatment

Rare diseases, including acquired orphan blood diseases, often have a limited number of treatment options available due to their low prevalence. This scarcity of therapies can make it difficult for patients to access appropriate treatments. Many orphan drugs and emerging therapies are associated with high treatment costs. The rarity of these diseases and the costs of research and development often result in expensive therapies, making them financially burdensome for patients and healthcare systems. Acquired orphan blood diseases are not always well-known among healthcare providers and the public. This lack of awareness can lead to delayed diagnoses and difficulty in accessing specialized treatments. Access to advanced medical treatments can vary significantly based on geographic location. Patients in remote or underserved areas may face challenges in accessing specialized healthcare facilities and therapies. In some regions, the healthcare infrastructure may not be adequately equipped to diagnose and manage acquired orphan blood diseases. This can lead to delays in treatment initiation. The availability and extent of insurance coverage for orphan blood disease therapies can vary widely. In some cases, insurance plans may not fully cover the cost of treatment, leaving patients with high out-of-pocket expenses. Pharmaceutical companies may encounter challenges in obtaining reimbursement approvals for orphan drugs, leading to delays in patients' access to treatment. Specialized treatment centers and healthcare providers with expertise in acquired orphan blood diseases may be concentrated in urban areas, making it challenging for patients in rural regions to access care.

Key Market Trends

Expanded Access Programs

(Expanded access programs) EAPs prioritize the needs of patients who have limited or no alternative treatment options. These programs provide access to potentially life-saving therapies, reflecting a patient-centered approach to healthcare. EAPs allow patients to access investigational or emerging therapies that are still in the clinical trial or regulatory approval phases. This can be especially valuable for patients with rare and life-threatening diseases like acquired orphan blood diseases. EAPs are driven by ethical considerations, recognizing the urgency of providing treatments to patients who may not qualify for clinical trials or cannot wait for regulatory approvals. They provide hope and potential benefits to those in need. Patients who do not respond to standard therapies or who have contraindications to traditional treatments may find EAPs as a viable option for accessing novel treatments tailored to their specific condition. EAPs allow for the collection of real-world data and evidence regarding the safety and efficacy of therapies in diverse patient populations. This information can complement clinical trial data and inform treatment decisions. EAPs involve close collaboration between physicians, patients, pharmaceutical companies, and regulatory authorities. This collaboration ensures that patients receive the most appropriate and personalized care.

Key Market Players

• Alexion Pharmaceuticals, Inc.
• Amgen, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Sanofi S.A.
• GlaxoSmithKline plc,
• Cyclacel Pharmaceuticals, Inc.
• Onconova Therapeutics, Inc.
• Incyte Corporation,
• CTI BioPharma Corp

Report Scope:

In this report, the Global Acquired Orphan Blood Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acquired Orphan Blood Diseases Therapeutics Market, By Therapy:

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Disease Indication:

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acquired Orphan Blood Diseases Therapeutics Market.

Available Customizations:

Global Acquired Orphan Blood Diseases Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others)
  • 5.2.2. By Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Disease Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy
      • 6.3.4.2.2. By Disease Indication
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy
      • 6.3.5.2.2. By Disease Indication
      • 6.3.5.2.3. By Distribution Channel

7. Europe Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Distribution Channel

8. North America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel

9. South America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Acquired Orphan Blood Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Alexion Pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Amgen, Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Celgene Corporation
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Eli Lilly and Company
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Sanofi SA
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. GlaxoSmithKline plc
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Cyclacel Pharmaceuticals Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Onconova Therapeutics, Inc
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Incyte Corporation
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.CTI BioPharma Corp
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer